Last reviewed · How we verify

NCT03298360: ANRS EP63

A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a

Completed Last updated 8 December 2020
What this trial tests

trial testing Blood sample in HIV Infections in 11 participants. Completed in 25 June 2020.

Timeline
28 June 2018
Primary endpoint
25 June 2019
25 June 2020

Quick facts

Lead sponsorANRS, Emerging Infectious Diseases
StatusCompleted
Study typeOBSERVATIONAL
Enrollment11
Start date28 June 2018
Primary completion25 June 2019
Estimated completion25 June 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients who have participated in the ANRS 139 TRIO trial, always followed and in virological success, and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to reconstruct the chronology of the installation of this reservoir.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03298360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing